Article Sidebar

PDF
Date Published: 13/02/2023
Abstract Views: 112
Views PDF: 89
DOI: https://doi.org/10.51298/vmj.v521i1.3984
Issue
Vol. 521 No. 1 (2022)
Section
Các bài báo
How to Cite
Trần, N. T., Nguyễn, P. H., Lê, P. T., & Dương, H. T. (2023). PCNA EXPRESSION IN GASTRIC ADENOCARRCINOMA. Vietnam Medical Journal, 521(1). https://doi.org/10.51298/vmj.v521i1.3984

PCNA EXPRESSION IN GASTRIC ADENOCARRCINOMA

Ngọc Thụy Trần1,, Phú Hùng Nguyễn2, Phong Thu Lê1, Hồng Thái Dương1
1 Thai Nguyen University Of Medicine And Pharmacy
2 Thai Nguyen University Of Science

Main Article Content

Abstract

Objectives: To evaluate the level of PCNA expression and its relationship with the endoscopic and histopathological features of patients with gastric antral adenocarcinoma. Subjects and methods: The study was performed on 150 cases of gastric adenocarcinoma operated at Hanoi K Hospital from january 2018 to december 2019, using an cross-sectional descriptive method. Results: High expression level of PCNA was found in 54,7% of gastric adenocarcinomas. High expression of PCNA in infiltrates, polyps, ulcers and polypoid was 33,3%, 50%, 53,8% and 61,1% (p > 0.05). According to Lauren's histological classification, 61,5% of intestinal type tumors had PNCA high expression compared to 29,4% of diffused types and 71,4% of mixed types, respectively (p < 0.01). High expression level of PCNA was different in papillary 100% mixed 71.4% tubular 63,6% mucinous 44.4% and signet ring cell 29,4% types (p < 0.05). High expression of PCNA in different grades: 41,4% of well-differentiated, 69,6% of moderately differentiated and 47,7% of poorly differentiated tumors (p < 0.05).

Article Details

Keywords

PCNA, gastric adenocacinoma, intestinal type, diffuse type

References

1. Sung H., Ferlay J. , Siegel R. L. (2021), "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries", CA Cancer J Clin, 71(3), pp.209-249.
2. Kamiya S., Rouvelas I., Lindblad M. , Nilsson M. (2018), "Current trends in gastric cancer treatment in Europe", Journal of Cancer Metastasis and Treatment,4, pp.35.
3. Matsusaka S., Nashimoto A., Nishikawa K., Miki A., Miwa H., Yamaguchi K. et al. (2016), "Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)", Gastric Cancer, 19(3), pp.839-851.
4. Li H., Sandhu M., Malkas L. H., Hickey R. J. , Vaidehi N. (2017), "How Does the Proliferating Cell Nuclear Antigen Modulate Binding Specificity to Multiple Partner Proteins?", J Chem Inf Model, 57(12), pp.3011-3021.
5. Yin S., Li Z., Huang J., Miao Z., Zhang J., Lu C. et al. (2017), "Prognostic value and clinicopathological significance of proliferating cell nuclear antigen expression in gastric cancer: a systematic review and meta-analysis", Onco Targets Ther, 10, pp.319-327.
6. Li N., Deng W., Ma J., Wei B., Guo K., Shen W. et al. (2015), "Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer", Med Oncol, 32(1), pp.433.
7. Lee K. E., Lee H. J., Kim Y. H., Yu H. J., Yang H. K., Kim W. H. et al. (2003), "Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer", Jpn J Clin Oncol, 33(4), pp.173-179.
8. Czyzewska J., Guzińska-Ustymowicz K., Pryczynicz A., Kemona A. , Bandurski R. (2009), "Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer", Folia Histochem Cytobiol, 47(2), pp.289-296.